SCHEMBL5217035

SCHEMBL5217035

c1ccc(Oc2ccc(-n3cc(-c4ccncn4)cn3)cc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 7/20 0.44
MKNK1 Q9BUB5 6/20 0.42
KCNH2 Q12809 2/20 0.41
CYP11B1 P15538 1/20 0.41
CYP11B2 P19099 1/20 0.41
HTR2B P41595 1/20 0.40
MTNR1A P48039 1/20 0.40
PDE10A Q9Y233 1/20 0.40
CCNC P24863 1/20 0.40
CDK8 P49336 1/20 0.40
GRM5 P41594 1/20 0.39
FYN P06241 1/20 0.39
MKNK2 Q9HBH9 1/20 0.39
MELK Q14680 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5668065 0.87 GRM4 (0.48) GRM4MKNK1KCNH2HTR2BMTNR1A
SCHEMBL30795132 0.85 GRM5 (0.53) GRM4MKNK1KCNH2CYP11B1CYP11B2
SCHEMBL3929889 0.85 GRM5 (0.53) GRM4MKNK1KCNH2CYP11B1CYP11B2
SCHEMBL5216814 0.81 GRM5 (0.45) GRM4MKNK1PDE10AGRM5MKNK2
SCHEMBL12203764 0.80 PDE10A (0.46) GRM4MKNK1PDE10AGRM5MELK
SCHEMBL5662955 0.78 GRM5 (0.51) GRM4MKNK1KCNH2HTR2BMTNR1A
SCHEMBL182016 0.78 ALKBH2 (0.46) GRM4PDE10ACCNCCDK8MELK
SCHEMBL28245414 0.78 PDE10A (0.46) GRM4MKNK1KCNH2HTR2BMTNR1A
SCHEMBL5216414 0.77 ALDH1A1 (0.47) GRM4KCNH2HTR2BMTNR1A
SCHEMBL12410593 0.77 CYP2A6 (0.47) GRM4MKNK1KCNH2HTR2BMTNR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1458383-B1 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO INC (US) 2007-11-21 EP claimed
EP-1458383-A4 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO INC (US) 2005-05-25 EP claimed
US-20050026963-A1 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK SHARP & DOHME LLC 2005-02-03 US claimed
EP-1458383-A2 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 Merck & Co., Inc. (US) 2004-09-22 EP claimed
WO-2003051833-A2 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO., INC. (US) 2003-06-26 WO claimed
US-7569592-B2 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK & CO., INC. (US) 2009-08-04 US disclosed
US-7569592-B2 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK & CO., INC. (US) 2009-08-04 US disclosed
WO-2003051833-A2 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO., INC. (US) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026963-A1 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 GRM5, GRIK5, GRIN2C GRM4 8/4885MKNK1 893/4885KCNH2 575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.